Compare BUUU & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUUU | GLSI |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.1M | 123.9M |
| IPO Year | 2025 | 2020 |
| Metric | BUUU | GLSI |
|---|---|---|
| Price | $8.39 | $20.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $39.00 |
| AVG Volume (30 Days) | 9.7K | ★ 432.5K |
| Earning Date | 01-06-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $6,328,425.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $158.62 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $3.67 | $7.78 |
| 52 Week High | $9.50 | $22.31 |
| Indicator | BUUU | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 91.37 |
| Support Level | N/A | $13.11 |
| Resistance Level | N/A | $13.76 |
| Average True Range (ATR) | 0.00 | 1.88 |
| MACD | 0.00 | 1.00 |
| Stochastic Oscillator | 0.00 | 90.54 |
BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.